Vanderbilt University

Other

Yeda Research and Develpment & Co. Ltd

Carl G Hellerqvist

Barbara D Wamil

Michal Neeman

Changlin Fu

Rinat Abramovitch

Artur W Wamil

Methods are provided for preventing or attenuating pathoangiogenic conditions by administering at least one GBS toxin receptor polypeptide or at least one immunogenic fragment thereof. Also provided are a composition that includes a GBS toxin receptor polypeptide and a method for making such a composition. In another embodiment of the invention, immunized animals also receive GBS toxin, immunocompatible antibodies to the GBS toxin receptor, and/or expanded autologous T cells to the GBS toxin receptor. Also included in this invention are methods of identifying additional GBS toxin receptors.

GBS toxin receptor compositions and methods of use

A novel GBS toxin receptor and methods for its preparation and use are provided. GBS toxin receptor polynucleotides and polypeptides and antibodies to GBS toxin receptor are provided, as well as detection, screening, and therapeutic methods and pharmaceutical compositions involving such polynucleotides, polypeptides and antibodies.

GBS toxin receptor antibodies

A novel GBS toxin receptor, and methods for its preparation and use are provided. GBS toxin receptor polynucleotides and polypeptides are provided as well as detection, screening, and therapeutic methods and pharmaceutical compositions involving such polynucleotides and polypeptides.

GBS toxin receptor

The method of the present invention provides a means for protecting a patient, including a transplant patient, from reperfusion injury by administering CM101 or GBS toxin isolated from Group B &bgr;-hemolytic Streptococcus bacteria. The present invention also includes a method to protect a tissue or organ against reperfusion injury in a transplant patient.

Facilitation of wound healing with CM101/GBS toxin

The present invention includes a means of treating a patient having a keloid. Specifically, the invention includes a method for excising the keloid and administering a GBS toxin isolated from Group B &bgr;-hemolytic Streptococcus bacteria.

Facilitation of keloid healing with CM101/GBS toxin

Neural injury may be advantageously treated with CM101, a polysaccharide toxin isolated from Group B &bgr;-hemolytic Streptococcus bacteria. CM1O1 treatment aids in the re-establishment of neuronal connectivity, at least partially inhibits scar formation, and increases the probability of survival during the critical period following injury to the central nervous system. Preexisting neural injuries having scar tissue are ameliorated by surgical excision of the scar tissue in conjunction with administration of CM101.

Facilitation of repair of neural injury with CM101/GBS toxin

A method of treating a chronic inflammatory disease such as rheumatoid arthritis or psoriasis includes treating a patient with a toxin derived from Group B &bgr;-hemolytic Streptococcus bacteria. The purified GBS toxin, or CM101, may be administered. intravenously to the patient in repeated doses.

Treatment of chronic inflammatory diseases with CM101/GBS toxin

A method for purifying a polysaccharide from group B &bgr;-hemolytic Streptococcus (GBS) bacteria includes contacting a bacterial fermentation stock with a hydrophobic interaction chromatography (HIC) resin. Additional steps may include a phenol/saline extraction and an ion exchange chromatography. The method results in a product having very high purity. The product of the purification provides a composition which is highly useful in both research and therapeutic settings.

Method for purifying GBS toxin/CM101

A method for purifying a polysaccharide from group B .beta.-hemolytic Streptococcus (GBS) bacteria includes contacting a bacterial fermentation stock with a hydrophobic interaction chromatography (HIC) resin. Additional steps may include a phenol/saline extraction and an ion exchange chromatography. The method results in a product having very high purity. The product of the purification provides a composition which is useful in both research and therapeutic settings.

Polysaccharide toxin from group B -62 hemolytic streptococcus (GBS)

A method of treating a chronic inflammatory disease such as rheumatoid arthritis or psoriasis includes treating a patient with a toxin derived from Group B .beta.-hemolytic Streptococcus bacteria. The purified GBS toxin, or CM101, may be administered intravenously to the patient in repeated doses.

Neural injury of the type resulting from trauma or surgery may be advantageously treated with a polysaccharide toxin derived from Group B .beta.-hemolytic Streptococcus (GBS) bacteria. Additionally, diseases characterized by neuronal degeneration or impairment of neuronal connectivity, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis may be treated with the GBS toxin. The GBS toxin is administered to the patient before, during, or after infliction of the neural injury and acts by minimizing gliosis and promoting the reestablishment of neuronal connectivity.

A method for purifying a polysaccharide from group B .beta.-hemolytic Streptococcus (GBS) bacteria includes contacting a bacterial fermentation stock with a hydrophobic interaction chromatography (HIC) resin. Additional steps may include a phenol/saline extraction and an ion exchange chromatography. The method results in a product having very high purity. The product of the purification provides a composition which is highly useful in both research and therapeutic settings.

The method of the present invention provides a means of treating a patient having a wound, especially by minimizing scarring and accelerating wound healing, by administering CM101 or GBS toxin isolated from Group B .beta.-hemolytic streptococcus bacteria. The method of the present invention also includes administration of CM101 or GBS toxin to surgery patients having tumors in order to facilitate wound healing and minimize the likelihood of tumor progression.

The invention relates to a polysaccharide toxin from group B .beta.-hemolytic Streptococcus (GBS) having improved purity. The improved purity of the toxin, 95%, is achieved by the method of purification wherein a bacterial fermentation stock is subjected to chromatography with hydrophobic interaction chromatography (HIC) resin, extraction with a phenol/saline solution followed by ion exchange chromatography. The purified GBS toxin has a molecular weight of about 300 kD and a relative carbohydrate ratio of rhamnose:mannose:galactose:glucose:N-acetyl glucosamine:N-acetyl galactosamine of about 0:1:3:1:1:1, respectively. The GBS toxin is useful for treatment of tumors and other medical conditions.

Growing community of inventors

Brentwood, TN, United States of America

Carl G Hellerqvist